Tolterodine + Mirabegron for Nocturia

This trial aims to evaluate the effectiveness of two medications, tolterodine and mirabegron, for treating urinary incontinence associated with sudden urgency in older women who can walk to the bathroom independently. Researchers will compare the impact of these medications on bladder control, cognitive abilities, and other age-related functions. Participants will be divided into three groups: one receiving tolterodine, another receiving mirabegron, and a third receiving a placebo (a harmless pill with no active medication) along with self-management strategies like timed urination and lifestyle changes. This trial may suit those experiencing sudden urgency-related urinary leaks for at least three months. As a Phase 4 trial, this research focuses on understanding how these FDA-approved treatments can benefit more patients.

Previous studies have shown that mirabegron is safe. Most people tolerate it well, and side effects are usually mild. Common side effects include high blood pressure, a sore throat, and a slight increase in blood sugar levels. No major safety issues have been reported.

Research has also confirmed the safety of tolterodine tartrate ER. It effectively reduces bladder symptoms with few side effects and is well-tolerated, even by older adults. Some people might experience dry mouth or constipation, but these effects are generally mild.

Researchers are excited about combining Tolterodine and Mirabegron for treating nocturia because these drugs offer a dual mechanism of action that targets different pathways associated with overactive bladder symptoms. Tolterodine is an anticholinergic that reduces bladder muscle contractions, while Mirabegron is a beta-3-adrenergic agonist that relaxes the bladder muscle. This combination might provide more comprehensive symptom relief compared to standard treatments, which typically focus on one pathway. Additionally, the inclusion of behavioral self-management education is anticipated to enhance patient outcomes by promoting lifestyle changes and exercises that support bladder health.

Research has shown that Mirabegron, one of the treatments in this trial, effectively treats symptoms of an overactive bladder. It reduces episodes of urge incontinence, characterized by a loss of bladder control, by about 23%. Patients with an overactive bladder report fewer side effects with Mirabegron compared to some other treatments. Tolterodine, another treatment option in this trial, relaxes the bladder muscles, helping to reduce the frequent need to urinate. It is well tolerated and improves bladder function, leading to fewer incontinence episodes. Both treatments have demonstrated significant improvements over a placebo in clinical studies.²⁶⁷⁸⁹